Table 3.
Multivariable Cox model for hospital admission or death among non-complicated COVID-19 patients treated with early antiviral treatment
| HRadj (95% CI)a | p-value | |
|---|---|---|
| Vaccination | ||
| No | Reference | |
| Yes | 0.31 (0.14–0.70) | 0.005 |
| Covid-19 severity | ||
| Mild | Reference | |
| Moderate | 12.23 (4.65–32.18) | < 0.001 |
| Time from symptoms onset to treatment (days) b (with time-varying HR) c | ||
| 0–1 | Reference | |
| 2 | 0.22 (0.05–1.11) | 0.068 |
| 3 | 0.51 (0.04-6.00) | 0.593 |
| More than 4 | 0.09 (0.01–0.66) | 0.019 |
aSurvey-weighted Cox regression model with inverse-probability weighting and design-based standard errors. HRadj: Hazard Ratio adjusted for sex
bCategories are based on quartiles
cTime-varying HR (HRtv) was calculated using: HRtv=exp [β1X + β2Xlog(t)] = HR(X)*exp[β2Xlog(t)]. For each category of time from symtpoms onset to treatment, we considered:
-category “2 days”: β1= -1.50, β2 = 0.70, HR = 0.22
HRtv=exp[-1.50 + 0.70*log(t)] = 0.22*exp[0.70*log(t)]
-category “3 days”: β1= -0.67, β2 = 0.54, HR = 0.51
HRtv=exp[-0.67 + 0.54*log(t)] = 0.51*exp[0.54*log(t)]
-category “More than 4 days”: β1= -1.18, β2 = 0.08, HR = 0.09
HRtv=exp[-1.18 + 0.08*log(t)] = 0.09*exp[0.08*log(t)]
The plot of these HRtv is reported in Fig. 2